For adults with complicated urinary tract infections, a new drug has been approved by the U.S. Food and Drug Administration.
Vabomere is an antibacterial drug that inhibits "certain types of resistance mechanisms used by bacteria," the FDA said in a news release today.
“The FDA is committed to making new safe and effective antibacterial drugs available,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research. “This approval provides an additional treatment option for patients with cUTI, a type of serious bacterial infection.”
In a clinical trial with 545 adults with complicated UTIs, 98 percent given the intravenous treatment improved. Seven days following treatment, 77 percent had resolved symptoms, the FDA said.
"The FDA granted approval of Vabomere to Rempex Pharmaceuticals," the release said.
A cUTI is different from a UTI in that the person who has one typically has another abnormality that leads to the complication, according to the National Institutes of Health.
